column
    Minimal Residual Disease: Leading The Cross-Age Biomarker for Lung Cancer
    ZHANG Jia-tao, YANG Xue-ning, WU Yi-long
    2021, 21(1): 1-5. DOI: 10.12019/j.issn.1671-5144.2021.01.001
    Abstract FullText HTML PDF
    The Prognostic and Predictive Role of Circulating Tumor DNA in Advanced Tumor Immunotherapy
    ZHU Bo, LU Hong-lian
    2021, 21(1): 6-9. DOI: 10.12019/j.issn.1671-5144.2021.01.002
    Abstract FullText HTML PDF
    Liquid Biopsy Reveals Radiotherapy Prognosis of Patients with Oligometastatic Non-Small Cell Lung Cancer
    ZHU Zheng-fei, QIU Zhen-bin
    2021, 21(1): 10-13. DOI: 10.12019/j.issn.1671-5144.2021.01.003
    Abstract FullText HTML PDF
    Something Varies Due To Different Conditions: EGFR Mutant Clonal Architecture Affects The Efficacy of EGFR Tyrosine Kinase Inhibitor
    HU Jie, WEI Xue-wu
    2021, 21(1): 14-17. DOI: 10.12019/j.issn.1671-5144.2021.01.004
    Abstract FullText HTML PDF
    Monitoring of Minimal Residual Disease And Prediction of Disease Recurrence by ctDNA
    LI Zi-ming, LU Shun, CHEN Zi-hao
    2021, 21(1): 18-20. DOI: 10.12019/j.issn.1671-5144.2021.01.005
    Abstract FullText HTML PDF
    Integrating Genomic Features for Non-Invasive Early Lung Cancer Detection
    ZHANG Xu-chao, YIN Kai
    2021, 21(1): 21-25. DOI: 10.12019/j.issn.1671-5144.2021.01.006
    Abstract FullText HTML PDF
    2020Research Advances in Lung Cancer
    QIU Zhen-bin, YANG Xue-ning, ZHONG Wen-zhao, WU Yi-long
    2021, 21(1): 26-30. DOI: 10.12019/j.issn.1671-5144.2021.01.007
    Abstract FullText HTML PDF
    Research Advances in Systemic Therapy of Advanced Hepatocellular Carcinoma in 2020
    HE Jian, CHEN Xiao-ming
    2021, 21(1): 31-32. DOI: 10.12019/j.issn.1671-5144.2021.01.008
    Abstract FullText HTML PDF
    2020 Clinical Research Advances in Gastrointestinal Cancer
    DONG Qiu-mei, MA Dong
    2021, 21(1): 33-36. DOI: 10.12019/j.issn.1671-5144.2021.01.009
    Abstract FullText HTML PDF
    2020 Clinical Research Advances in Tumor Radiotherapy
    CHEN Zhi-yong, PAN Yi
    2021, 21(1): 37-40. DOI: 10.12019/j.issn.1671-5144.2021.01.010
    Abstract FullText HTML PDF
    2020 Research Advances in Lymphoma Treatment
    LIU Si-chu, LI Wen-yu
    2021, 21(1): 41-44. DOI: 10.12019/j.issn.1671-5144.2021.01.011
    Abstract FullText HTML PDF
    Research Advances of Targeted Immune Checkpoint Therapy for Hematologic Tumor in 2020
    GENG Su-xia, DU Xin
    2021, 21(1): 45-49. DOI: 10.12019/j.issn.1671-5144.2021.01.012
    Abstract FullText HTML PDF
    Milestone Progress in Precision Treatment of Breast Cancer: 2020 Clinical Research Advances of Breast Cancer
    LAI Jian-guo, LIAO Ning
    2021, 21(1): 50-53. DOI: 10.12019/j.issn.1671-5144.2021.01.013
    Abstract FullText HTML PDF
    Risk of COVID-19 among Front-Line Health-Care Workers During The COVID-19 Pandemic
    CHEN Xiu-mei, FU Rui, DENG Qian-yun, YAN Hong-hong, YANG Jin-ji, ZHANG Xu-chao, ZHOU Qing, QIAO Gui-bin, YANG Xue-ning, PAN Yi, LI Rui-na, LEI Li-chan, ZHAO Shun-zhen, WU Jian-hong, GAN Bin, ZHONG Wen-zhao, HOU Tie-ying, WU Yi-long
    2021, 21(1): 54-59. DOI: 10.12019/j.issn.1671-5144.2021.01.014
    Abstract FullText HTML PDF
    Therapeutic Strategy for Patients with Non-Small Cell Lung Cancer Complicated with Lung Abscess Infection
    ZHENG Ming-ying, ZHOU Qing
    2021, 21(1): 60-64. DOI: 10.12019/j.issn.1671-5144.2021.01.015
    Abstract FullText HTML PDF